Odomzo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178563 SUN PHARM Compounds and compositions as hedgehog pathway modulators
Jul, 2029

(5 years from now)

US8063043 SUN PHARM Salts of N-[6-cis-2,6-dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4′-(trifluoromethoxy)[1,1′-biphenyl]-3-carboxamide
Sep, 2029

(5 years from now)

US10266523 SUN PHARM Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
Mar, 2036

(12 years from now)

Odomzo is owned by Sun Pharm.

Odomzo contains Sonidegib Phosphate.

Odomzo has a total of 3 drug patents out of which 0 drug patents have expired.

Odomzo was authorised for market use on 24 July, 2015.

Odomzo is available in capsule;oral dosage forms.

Odomzo can be used as treatment of basal cell carcinoma.

The generics of Odomzo are possible to be released after 30 March, 2036.

Drugs and Companies using SONIDEGIB PHOSPHATE ingredient

Market Authorisation Date: 24 July, 2015

Treatment: Treatment of basal cell carcinoma


More Information on Dosage

ODOMZO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic